Piper Sandler Sticks With Overweight on Natera, Cites Japan as Major Market Opportunity
Piper Sandler has reaffirmed an Overweight rating and a $230 price target on Natera (NTRA), citing a roughly 12% upside from the prevailing share price and pointing to Japan as a potentially underappreciated growth market for the company’s Signatera test. The firm emphasized a 2026 approval target in Japan and commercialization with reimbursement i…